Get the Stockscreener App
199.59
0.93%
1.84
After Hours:
199.59
Charles River Laboratories International Inc stock is traded at $199.59, with a volume of 238.55K.
It is up +0.93% in the last 24 hours and up +9.59% over the past month.
See More
Previous Close:
$197.75
Open:
$200.05
24h Volume:
238.55K
Relative Volume:
0.34
Market Cap:
$10.63B
Revenue:
$4.08B
Net Income/Loss:
$431.79M
P/E Ratio:
21.17
EPS:
9.43
Net Cash Flow:
$486.92M
1W Performance:
+6.22%
1M Performance:
+9.59%
6M Performance:
-8.11%
1Y Performance:
+2.51%
1-Day Range:
$198.23
$202.56
1-Week Range:
$186.62
$202.87
52-Week Range:
$176.48
$275.00
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
199.59 | 10.63B | 4.08B | 431.79M | 486.92M | 9.43 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Mudita Advisors LLP Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles Schwab Investment Management Inc. Purchases 32,311 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
While shareholders of Charles River Laboratories International (NYSE:CRL) are in the red over the last three years, underlying earnings have actually grown - Simply Wall St
Charles River labs accused of exploiting loophole to move monkeys through Canada - Montreal Gazette
Charles River Labs shares target cut, rating held on Q2 results - Investing.com Canada
Charles River Laboratories International Inc (CRL) Stock Price U - GuruFocus.com
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Citigroup Inc. - MarketBeat
Horizon Kinetics Asset Management LLC Sells 45,619 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Reduce" from Analysts - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 63,588 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Large Molecule Bioanalytical Technologies Market Research Explores Drivers And Growth Report 2033 - WhaTech
Lathrop Investment Management Corp Cuts Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
King Luther Capital Management Corp Sells 252,657 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Brown Capital Management LLC Sells 13,542 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Medical Device Testing Services Market Growth, Size, Trends, - openPR
Charles River Laboratories To Present At Jefferies London Healthcare Conference; Webcast At 9:00 AM - Nasdaq
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Premier Fund Managers Ltd - MarketBeat
Charles River Labs closes several locations, 1,300+ jobs cut in cost saving initiative - MSN
Major Player in the Biomarker Clinical Phase Outsourcing - openPR
Drug Discovery Outsourcing Services Market to Achieve a Superb - openPR
Natixis Advisors LLC Lowers Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle - Seeking Alpha
Bioprocess Validation Market to Witness 9.10% CAGR by 2031 | SkyQuest Technology - Benzinga
Thrivent Financial for Lutherans Decreases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Mawer Investment Management Ltd. - MarketBeat
CLSA Downgrades Charles River Laboratories International (NYSE:CRL) to Underperform - MarketBeat
Sumitomo Mitsui Trust Group Inc. Grows Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Mizuho Securities USA LLC Buys 92,895 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
KBC Group NV Has $16.66 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Holdings Decreased by Victory Capital Management Inc. - MarketBeat
Entropy Technologies LP Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Entropy Technologies LP Trims Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Empower Advisory Group LLC Sells 3,497 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Labs to close Skokie office - Crain's Chicago Business
Charles River Laboratories To Present At UBS Global Healthcare Conference; Webcast At 1:15 PM ET - Nasdaq
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by WCM Investment Management LLC - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Position Lowered by Amalgamated Bank - MarketBeat
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024. - Marketscreener.com
Genotoxicity Tests Market Trends Detailed Research and Projected Growth through 2032 - WICZ
Charles River Laboratories to Present at UBS and Jefferies Conferences - sharewise
Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):